Results 191 to 200 of about 379,925 (396)
An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population
Clinical Anatomy, EarlyView.ABSTRACT This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as ...
Amy C. Beresheim, Amanda Hall
wiley +1 more source
Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer—Where is the evidence? [PDF]
, 2018 Jessica L. Gray +3 more
openalex +1 more source
Health-Related Quality of Life in Patients with Low-Risk Differentiated Thyroid Cancer: A Systematic Review Examining the Extent of Thyroidectomy [PDF]
, 2023 Kathy Bach +6 more
openalex +1 more source
Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review
Clinical Anatomy, EarlyView.ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner +13 more
wiley +1 more source
Reply to “Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer” [PDF]
, 2018 Norman G. Nicolson, Tobias Carling
openalex +1 more source
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
Clinical Pharmacology &Therapeutics, EarlyView.Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg +10 more
wiley +1 more source